PeptiDream Inc. (PPTDF)
10.94
0.00 (0.00%)
USD |
OTCM |
Dec 05, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.414B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -35.62% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 11.79 |
| Price to Book Value | 3.971 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3488 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 87.73% |
Profile
| PeptiDream, Inc. engages in the biopharmaceutical business that includes research and development of non-standard peptide therapeutics. It operates through Drug Discovery and Development Business segment. The Drug Discovery and Development Business segment provides macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS) and engages in collaborative drug discovery research and development, technology licensing of PDPS, and expansion of pipeline through strategic alliances. The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan. |
| URL | http://www.peptidream.com |
| Investor Relations URL | N/A |
| HQ State/Province | Kanagawa |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 12, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| PeptiDream, Inc. engages in the biopharmaceutical business that includes research and development of non-standard peptide therapeutics. It operates through Drug Discovery and Development Business segment. The Drug Discovery and Development Business segment provides macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS) and engages in collaborative drug discovery research and development, technology licensing of PDPS, and expansion of pipeline through strategic alliances. The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan. |
| URL | http://www.peptidream.com |
| Investor Relations URL | N/A |
| HQ State/Province | Kanagawa |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 12, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |